Spero Therapeutics, Inc. (SPRO) AI Stock Summary

Snapshot

Spero Therapeutics is a clinical-stage biotech that successfully partnered its drug Utebzi with GSK. FY 2025 revenue jumped to $59.6M with $8.6M in net income, but Q1 2026 revenue collapsed to $258K, indicating the 2025 numbers were likely one-time collaboration milestones. The company holds $40.3M in cash against $2.9M of debt and burns about $12.6M annually, giving it a stated cash runway into 2028. Despite this progress, the stock trades in the lower portion of its 52-week range and short interest has surged 218% in three months.

What's Happening Right Now

• Wed 17th Jun '26 · Regulatory approval: Spero and GSK received FDA approval for Utebzi to treat complicated urinary tract infections in adults.
• Wed 13th May '26 · Earnings: Spero reported first quarter 2026 results, reaffirming a cash runway into 2028 while the FDA reviews its drug application.

Ownership

Institutions hold 36.8% and insiders hold 8.4%.

Bottom Line

Spero is a rare case where a company achieved a major FDA approval but the stock sold off, leaving it near the bottom of its yearly range. The business is transitioning from burning cash on development to collecting royalties from GSK, though current revenue is minimal until sales launch. With enough cash to last into 2028, the immediate risk is market adoption rather than survival, but the surge in short interest suggests skepticism remains high.